Soleno Therapeutics requests Nasdaq delisting after merger completion

Soleno Therapeutics Inc

Soleno Therapeutics Inc

SLNO

0.00
  • Soleno Therapeutics on May 18, 2026 requested Nasdaq suspend trading and delist its shares following completion of its merger.
  • The company also expects Nasdaq to file a Form 25 with the SEC to remove the shares from listing and registration under Exchange Act Section 12(b).
  • It plans to file a Form 15 to terminate registration under Exchange Act Section 12(g) and suspend SEC reporting obligations under Sections 13 and 15(d).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-228016), on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.